Bioflow-DAPT Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1948 participants.

Also called NCT04137510

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,948 participants (enrolled count) (from the registry)
Sponsor
  • Biotronik AG Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04137510
Other papers using this trial's data
  • Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial European heart journal. Acute cardiovascular care, 2026-08-29 DOI, PubMed 42555546
  • Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial Circulation, 2023-09-26 DOI, PubMed 37624364, PMC10516164 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Austria, Belgium, Denmark, France, Germany, Hong Kong SAR China, Hungary, Italy, Latvia, Malaysia, Netherlands, New Zealand, Poland, Singapore, Spain, Switzerland, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04137510. Randomized; no masking; primary purpose treatment. Start 2020-02-24 (actual); primary completion 2022-09-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bioflow-DAPT Study
Lead sponsor
Biotronik AG (class: industry)

Record details

Record id
cardio:ct-nct04137510
Content hash
48fdb509fded3c097a911ce3f1379215d32b814c603b82fc12a112fcb45d8be8